Ann: Lumos Signs Major Development and IP Agreements with Hologic, page-117

As mentioned previously, some key things to understand about the market:

- CPT code reimbursement is not standard practice across Europe/UK. Therefore potential uptake is slower than in AUS/US. US would be the focus as it is a substantially larger market than AUS.

- Market shift from auto prescribing antibiotics to running these diagnostics tests at point of patient care. It will require a change of procedure with most doctors offices etc. This is harder in Europe than US because of the above as well.

Anyone remember A2M? The stock was doing okay in Australia when it was selling product in AUS. Once the Chinese market started pilfering every single can of formula, the market opened up, the stock price went off.

The US here would be our Chinese market and any other revenues from other locations wont appear as great, but still adding to the mix.